- Home
- MUFG vs NVO Comparison
MUFG vs NVO Comparison
Compare MUFG & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | NVO |
|---|---|---|
| Founded | 1880 | 1923 |
| Country | Japan | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.1B | 203.2B |
| IPO Year | 2002 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MUFG | NVO |
|---|---|---|
| Price | $22.24 | $48.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $51.00 |
| AVG Volume (30 Days) | 3.0M | ★ 12.4M |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | 2.32% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | N/A |
| Revenue Next Year | $10.12 | $3.70 |
| P/E Ratio | $25.47 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.65 | $35.12 |
| 52 Week High | $23.25 | $64.16 |
Technical Indicators
Market Signals| Indicator | MUFG | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 54.56 |
| Support Level | $21.81 | $47.93 |
| Resistance Level | $23.11 | $50.45 |
| Average True Range (ATR) | 0.27 | 0.95 |
| MACD | -0.13 | 0.13 |
| Stochastic Oscillator | 38.86 | 94.29 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.